2023: The decline of Covid-19 testing
GlobalData predicts that Covid-19 testing and other related products will continue to drop in 2023.
We will see a shift towards companies producing rapid tests and home testing kits that can be used by the public. Credit: Noiel / Shutterstock.com.
2023 will be a pivotal year for many diagnostic companies as they move away from Covid-19 testing to other ventures. Companies are looking to diversify offers,
use research from Covid-19 test development in other tests, and reinvest research and development (R&D) into other diseases. We will see a shift towards
companies producing rapid tests and home testing kits that can be used by the public and a focus on point-of-care (POC) tests, as opposed to laboratory tests.
Abbott highlighted that although there will be drop-in Covid-19 testing alone, there will be increased testing in respiratory diseases like in multiparameter tests
to differentiate between Covid-19, influenza, and respiratory syncytial virus. These changes are indicative of a shrinking Covid-19 market. Therefore, many of these
companies are shifting their R&D towards developing POC tests and over-the-counter tests to not only decrease turnover time on test results, but to also cater to
more individuals who are interested in getting involved in their own healthcare.
While testing for COVID-19 is on the wane and may even disappear in the next few years, other human health tests will not stop, this means that those diagnostic
companies should continue to expand the range of tests, making them more extensive and comprehensive.
As a strong support for all diagnostic companies, life sciences, forensic, cell, virus and microbial collection, medical testing institutions, Mandelab will continue to
produce and supply all kinds of superior quality disposable sampling swabs as needed. We will continue to work closely with each other and fulfill our destiny.
By Michael 30, Jan. 2023
